Evotec receives € 3 million payment from Sanofi

Evotec achieves third milestone in cell therapy diabetes alliance with Sanofi

20-Dec-2019 - Germany

Evotec SE announced successful achievement of a third milestone in their diabetes research alliance with Sanofi (“TargetBCD”), resulting in a payment of € 3 m to Evotec.

This milestone was triggered after Evotec met pre-agreed critical criteria within the beta cell replacement therapy programme. The ultimate goal of the collaboration is to develop a beta cell replacement therapy for people with diabetes based on beta cells derived from human induced pluripotent stem cells.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are extremely pleased with the progress we are making on this beta cell therapy approach which has the potential to restore beta cell function and, thereby, address the root cause of diabetes rather than only its symptoms.”

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance